Moderna Q1 2024 GAAP EPS $(3.07) Beats $(3.55) Estimate, Sales $167.000M Beat $97.501M Estimate
Portfolio Pulse from Benzinga Newsdesk
Moderna reported Q1 2024 GAAP EPS of $(3.07), surpassing the $(3.55) estimate, with sales of $167M also beating the $97.501M forecast. Despite beating estimates, this represents a significant decrease from the previous year's earnings and sales.
May 02, 2024 | 10:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's Q1 2024 earnings and sales exceeded expectations, but showed a steep decline from the previous year.
Beating both EPS and sales estimates typically has a positive short-term impact on a company's stock price. However, the significant year-over-year decline in earnings and sales might temper investor enthusiasm, suggesting a cautious optimism.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100